SMARCB1 and epithelioid sarcoma: In a phase II trial of EZH2-inhibitor tazemetostat for people > 16 years with SMARCB1-deficient advanced epithelioid sarcoma, 15% had an objective response and the median progression-free survival was 5.5 months, prompting FDA approval [86].